Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | MGAM | O43451 | 1/20 | 0.44 |
| ▸ | SI | P14410 | 1/20 | 0.44 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.44 |
| ▸ | CYP4F2 | P78329 | 4/20 | 0.43 |
| ▸ | CYP4A11 | Q02928 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | CPT2 | P23786 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7668564 | 0.89 | GAA (0.50) | GAAMGAMSIMGAM2CYP4F2 | |
| SCHEMBL22070619 | 0.88 | CYP4F2 (0.53) | GAAMGAMSIMGAM2CYP4F2 | |
| SCHEMBL13732997 | 0.88 | CYP4F2 (0.36) | GAAMGAMSIMGAM2CYP4F2 | |
| SCHEMBL4996013 | 0.87 | GAA (0.48) | GAAMGAMSIMGAM2CYP4F2 | |
| SCHEMBL232993 | 0.84 | GAA (0.55) | GAAMGAMSIMGAM2CYP4F2 | |
| SCHEMBL15012601 | 0.83 | TDP1 (0.54) | GAAMGAMSIMGAM2CYP4F2 | |
| SCHEMBL2991171 | 0.83 | TDP1 (0.54) | GAAMGAMSIMGAM2CYP4F2 | |
| SCHEMBL9512942 | 0.82 | BHMT (0.39) | GAAMGAMSIMGAM2CYP4F2 | |
| SCHEMBL6898390 | 0.82 | GAA (0.43) | GAAMGAMSIMGAM2CYP4F2 | |
| SCHEMBL9511916 | 0.82 | ALDH1A1 (0.50) | GAAMGAMSIMGAM2CYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9487492-B2 | Dibenzothiazepine derivatives and their use in the treatment of CNS disorders | NUMEDICUS LIMITED (GB) | 2016-11-08 | — | — | US | disclosed |
| EP-2699559-B1 | DIBENZOTHIAZEPINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | NUMEDICUS LTD (GB) | 2016-04-06 | — | — | EP | disclosed |
| US-20140243317-A1 | DIBENZOTHIAZEPINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | NUMEDICUS LIMITED (GB) | 2014-08-28 | — | — | US | disclosed |
| EP-2699559-A1 | DIBENZOTHIAZEPINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | Numedicus Limited (GB) | 2014-02-26 | — | — | EP | disclosed |
| WO-2012143703-A1 | DIBENZOTHIAZEPINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | NUMEDICUS LIMITED (GB) | 2012-10-26 | — | — | WO | disclosed |
| WO-2010039531-A1 | THERAPEUTIC COMPOUNDS | RESOLVYX PHARMACEUTICALS, INC. (US) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243317-A1 | DIBENZOTHIAZEPINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | SLC6A3, DRD1, AVPR2 | GAA 2990/4885MGAM 3053/4885SI 4360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.